Spots Global Cancer Trial Database for Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion
Official Title: A Single-center, Open-label, Fixed-sequence Phase I Drug-drug Interaction Clinical Study to Investigate the Pharmacokinetics of SHR3680 With Repaglinide (CYP2C8 Substrates) and Bupropion (CYP2B6 Substrates) in Prostate Cancer Patients
Study ID: NCT04664725
Conditions
Interventions
Study Description
Brief Summary: The DDI study had been designed to investigate the effect of SHR3680 on the pharmacokinetics of Repaglinide and Bupropion
Detailed Description:
Keywords
Eligibility
Minimum Age: 45 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Hunan Cancer Hospital, Changsha, Hunan, China
Contact Details
Name: Weiqing Han, Ph.D
Affiliation: Hunan Cancer Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
